

Elena Gershtein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3986191/publications.pdf>

Version: 2024-02-01

68
papers

568
citations

687220

13
h-index

752573

20
g-index

72
all docs

72
docs citations

72
times ranked

762
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?. Breast Cancer Research and Treatment, 2006, 100, 1-11.	1.1	112
2	Phosphatidylinositol 3-kinase expression in human breast cancer. Clinica Chimica Acta, 1999, 287, 59-67.	0.5	30
3	Insulin-Like Growth Factors (IGF), IGF-Binding Proteins (IGFBP), and Vascular Endothelial Growth Factor (VEGF) in Blood Serum of Patients with Colorectal Cancer. Bulletin of Experimental Biology and Medicine, 2014, 156, 684-688.	0.3	22
4	Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma. Bulletin of Experimental Biology and Medicine, 2019, 166, 353-357.	0.3	20
5	Matrix Metalloproteinases 2, 7, and 9 in Tumors and Sera of Patients with Breast Cancer. Bulletin of Experimental Biology and Medicine, 2011, 151, 359-362.	0.3	18
6	Matrix Metalloproteinases 2, 7, and 9 and Tissue Inhibitor of Metalloproteinases-1 in Tumors and Serum of Patients with Ovarian Neoplasms. Bulletin of Experimental Biology and Medicine, 2010, 149, 628-631.	0.3	17
7	Matrix Metalloproteinases 2, 7, 9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in the Sera of Patients with Bone Tumors. Bulletin of Experimental Biology and Medicine, 2010, 149, 233-235.	0.3	16
8	Vascular Endothelial Growth Factor and Its Type 2 Receptor in Hepatocellular Carcinoma. Bulletin of Experimental Biology and Medicine, 2010, 149, 749-752.	0.3	15
9	Content of Matrix Metalloproteinase-8 and Matrix Metalloproteinase-9 in Oral Fluid of Patients with Chronic Generalized Periodontitis. Bulletin of Experimental Biology and Medicine, 2011, 152, 240-244.	0.3	15
10	Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors. Bulletin of Experimental Biology and Medicine, 2016, 160, 814-816.	0.3	15
11	Modern approaches to kidney cancer immunotherapy. Onkourologiya, 2018, 14, 54-67.	0.1	15
12	The role of phosphatidylinositol 3-kinase in the regulation of cell response to steroid hormones. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1450, 434-443.	1.9	14
13	Role of vascular endothelial growth factor during breast cancer. Bulletin of Experimental Biology and Medicine, 2002, 133, 521-528.	0.3	14
14	CLINICAL PROSPECTS OF TUMOR-ASSOCIATED PROTEASES AND THEIR TISSUE INHIBITORS INVESTIGATION IN ONCOLOGIC PATIENTS. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2013, 68, 16-27.	0.2	12
15	Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bulletin of Experimental Biology and Medicine, 2001, 131, 67-72.	0.3	11
16	Kidney Injury Molecule-1 (KIM-1) in Blood Plasma of Patients with Clear-Cell Carcinoma. Bulletin of Experimental Biology and Medicine, 2019, 167, 388-392.	0.3	11
17	Matrix metalloproteinases 7 and 9 and their types 1 and 4 tissue inhibitors in tumors and plasma of patients with colorectal cancer. Bulletin of Experimental Biology and Medicine, 2007, 143, 459-462.	0.3	10
18	Matrix Metalloproteinases and Inflammatory Cytokines in Oral Fluid of Patients with Chronic Generalized Periodontitis and Various Construction Materials. Bulletin of Experimental Biology and Medicine, 2012, 153, 72-76.	0.3	10

#	ARTICLE	IF	CITATIONS
19	Matrix metalloproteinases 2, 3, 13 and their type 2 tissue inhibitor in tumors and plasma of patients with colorectal cancer. Bulletin of Experimental Biology and Medicine, 2008, 145, 362-366.	0.3	9
20	Receptor Activator of Nuclear Transcription Factor NF- κ B (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. Bulletin of Experimental Biology and Medicine, 2017, 163, 478-481.	0.3	9
21	Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer. Bulletin of Experimental Biology and Medicine, 2019, 166, 373-376.	0.3	9
22	Vascular Endothelial Growth Factor and Type 2 Receptor for This Factor in Vascular Malformations. Bulletin of Experimental Biology and Medicine, 2011, 150, 481-484.	0.3	8
23	Prognostic Role of Tumor-Associated Proteases in Colorectal Cancer. Bulletin of Experimental Biology and Medicine, 2013, 154, 365-369.	0.3	8
24	Soluble forms of the immune check-point receptor PD-1 and its ligand PD-L1 in blood serum of patients with renal cell carcinoma: clinical and pathologic correlations. Onkourologiya, 2019, 15, 15-22.	0.1	8
25	Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer. Bulletin of Experimental Biology and Medicine, 2008, 145, 245-248.	0.3	7
26	The Expression and DNA-Binding Activity of NF- κ B Nuclear Transcription Factor in the Tumors of Patients with Breast Cancer. Bulletin of Experimental Biology and Medicine, 2010, 150, 71-74.	0.3	7
27	Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients. Bulletin of Experimental Biology and Medicine, 2017, 163, 250-254.	0.3	7
28	Key Immune Checkpoint PD-1/PD-L1 Signaling Pathway Components in the Blood Serum from Patients with Bone Tumors. Bulletin of Experimental Biology and Medicine, 2020, 170, 64-68.	0.3	7
29	Comparative analysis of the sensitivity of endometrial cancer cells to epidermal growth factor and steroid hormones. Cancer, 1995, 76, 2524-2529.	2.0	6
30	Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bulletin of Experimental Biology and Medicine, 2001, 132, 670-674.	0.3	6
31	Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. Bulletin of Experimental Biology and Medicine, 2001, 132, 780-782.	0.3	6
32	Matrix Metalloproteinases and Their Tissue Inhibitors in Blood Serum of Patients with Endometrial Cancer: Clinical and Morphological Correlations. Bulletin of Experimental Biology and Medicine, 2018, 165, 75-79.	0.3	6
33	Vascular endothelial growth factor in tumor tissue and blood serum from patients with breast cancer. Bulletin of Experimental Biology and Medicine, 2003, 135, 85-88.	0.3	5
34	Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer. Bulletin of Experimental Biology and Medicine, 2008, 145, 744-747.	0.3	5
35	Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer. Doklady Biochemistry and Biophysics, 2021, 497, 66-70.	0.3	5
36	Title is missing!. Molecular Biology, 2003, 37, 585-590.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Role of Phosphatidylinositol-3 Kinase in Regulation of Differential Sensitivity of Melanoma Cells to Antitumor Agents. A Model for Hormone Resistance Development in Tumor Cells. <i>Biochemistry (Moscow)</i> , 2004, 69, 322-330.	0.7	4
38	Activated Proteinkinase B in Breast Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2005, 139, 608-610.	0.3	4
39	Soluble fragment of Her2/neu receptor in the serum of patients with breast cancer with different levels of this protein expression in the tumor. <i>Bulletin of Experimental Biology and Medicine</i> , 2007, 143, 449-451.	0.3	4
40	Relationship between the Expression of VEGF Signal Components and Matrix Metalloproteinases in Ovarian Tumors. <i>Bulletin of Experimental Biology and Medicine</i> , 2011, 151, 449-453.	0.3	4
41	Comparative Analysis of Blood Plasma Proteome in Patients with Renal Cell Carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2019, 167, 91-96.	0.3	4
42	Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 168, 673-676.	0.3	4
43	Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 139-146.	0.2	4
44	Expression of phosphatidylinositol-3 kinase in lung cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2000, 130, 1166-1168.	0.3	3
45	Sensitization of MCF-7 breast cancer cells to the apoptotic effect of estradiol. <i>Bulletin of Experimental Biology and Medicine</i> , 2006, 141, 357-360.	0.3	3
46	Urokinase and Tissue Plasminogen Activators and Their PAI-1 Inhibitor in Tumors of Patients with Oral Mucosal Cancer: Relationship with the Main Clinical Morphological Factors. <i>Bulletin of Experimental Biology and Medicine</i> , 2010, 149, 347-350.	0.3	3
47	Clinical prospects of IGF-signaling system components study in ovarian cancer patients. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 75-85.	0.3	3
48	Regulatory Proteins of Epithelial-Mesenchymal Transition and Some Components of VEGF Signaling Pathway in Breast Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 802-806.	0.3	3
49	Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients. <i>Onkourologiya</i> , 2021, 16, 39-47.	0.1	3
50	Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1 / PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2020, 65, 669-675.	0.2	3
51	Clinical and prognostic importance of expression of epidermal growth factor receptors in non-small-cell lung carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 1999, 127, 404-407.	0.3	2
52	Comparative Analysis of MMP-8 and MMP-9 Concentrations in Crevicular and Peri-Implants Sulcular Fluids. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 170, 19-23.	0.3	2
53	Vascular Endothelial Growth Factor and Soluble Forms of Its Receptors 1 and 2 in Gastric Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2021, 170, 791-794.	0.3	2
54	Changes in relations between two pathways of synthesis of RNA precursors in the tissues of animals with fast growing hepatomas. <i>Bulletin of Experimental Biology and Medicine</i> , 1979, 87, 264-266.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Epidermal growth factor receptors in endometrial adenomatosis. Bulletin of Experimental Biology and Medicine, 1999, 127, 40-43.	0.3	1
56	Dependence of antitumor effect of hormonal cytostatic cortifen on expression of glucocorticoid receptors in brain tumor cells. Bulletin of Experimental Biology and Medicine, 1999, 127, 299-300.	0.3	1
57	Prognostic significance of the TNM system criteria, levels of serum insulin-like growth factors and their transport proteins, VEGF and MMP-7 in colorectal cancer. Klinicheskaya Laboratornaya Diagnostika, 2021, 66, 459-464.	0.2	1
58	Clinical and prognostic significance of the soluble form of the VISTA immunity control point in patients with primary bone tumors. Klinicheskaya Laboratornaya Diagnostika, 2021, 66, 533-538.	0.2	1
59	CLINICAL AND LABORATORY EVALUATION OF THE EFFECTIVENESS OF THE APPLICATION OF NONSTEROID ANTI-INFLAMMATORY PREPARATION OF THE COXIB GROUP. Archiv Euromedica, 2019, 9, 160-164.	0.1	1
60	Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer. Molecular Biology, 2020, 54, 870-875.	0.4	1
61	Prognostic significance of VEGF signaling system components and matrix metalloproteinases in blood serum of gastric cancer patients. Klinicheskaya Laboratornaya Diagnostika, 2021, 66, 650-654.	0.2	1
62	Action of tamoxifen on the reproductive organs of guinea pigs. Bulletin of Experimental Biology and Medicine, 1982, 94, 1713-1715.	0.3	0
63	Receptors for the epidermal growth factor and estrogens in primary bone tumors. Bulletin of Experimental Biology and Medicine, 1996, 122, 720-723.	0.3	0
64	Molecular Markers of Tumors. Bulletin of Experimental Biology and Medicine, 2009, 148, 230-237.	0.3	0
65	RECEPTOR ACTIVATOR OF NUCLEAR TRANSCRIPTION FACTOR NF- κ B (RANK), ITS LIGAND (RANKL) AND NATURAL INHIBITOR OSTEOPROTEGERIN (OPG) IN BLOOD SERUM OF PRIMARY BONE TUMOR PATIENTS: ASSOCIATION WITH CLINICOPATHOLOGICAL FEATURES AND INFLAMMATORY CYTOKINES LEVELS. , 0, , .		0
66	CLINICAL CHARACTERISTICS OF MATRIX METALLOPROTEINASES 2, 7, 9 AND THEIR TISSUE INHIBITORS 1 AND 2 TYPE IN THE BLOOD SERUM OF PATIENTS WITH CANCER ENDOMETRY. Problems of Biological Medical and Pharmaceutical Chemistry, 2018, 21, .	0.0	0
67	Key VEGF signaling system components and matrix metalloproteinases in the diagnosis and prognosis of overall survival of patients with renal cell cancer. Al'manah Klinicheskoy Meditsiny, 2020, 48, 78-83.	0.2	0
68	Soluble forms of PD-1/PD-L immune checkpoint receptor and ligand in blood serum of breast cancer patients: association with clinical pathologic factors and molecular type of the tumor. Klinicheskaya Laboratornaya Diagnostika, 2022, 67, 76-80.	0.2	0